Chengda Pharmaceuticals Hits Day Low of CNY 37.42 Amid Price Pressure

Chengda Pharmaceuticals Co., Ltd. experienced significant volatility on March 23, 2026, with the stock declining by 7.34% and reaching an intraday low of CNY 37.42. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% on the same day. Over the past week, Chengda's stock has seen a more pronounced decline of 12.38%, while its monthly performance reflects an 8.77% decrease. Despite these short-term challenges, the company has shown a remarkable annual performance, boasting a 91.09% increase compared to the same period last year. Financial metrics indicate some underlying concerns for Chengda Pharmaceuticals. The company has reported a low Return on Capital Employed (ROCE) of 7.29%, suggesting limited profitability relative to its capital. Additionally, net sales have contracted at an annual rate of 0.61%, and operating profit has seen a dramatic decline of 185.15% over the past five years. The company has also faced negative results for four consecutive quarters, raising questions about its operational efficiency and long-term growth prospects.